Jan 31 (Reuters) – Merck & Co’s (MRK.N) new antiviral pill, once touted as a potential game changer for treating COVID-19, is the last choice among four available options for at-risk patients given its relatively low efficacy and potential safety issues, U.S. doctors, healthcare systems and pharmacies told Reuters. […]
Merck’s COVID pill is last choice for U.S. patients, global use varies
![Merck’s COVID pill is last choice for U.S. patients, global use varies](https://www.gbcspt.com/wp-content/uploads/2022/02/QNK7QV6EBFIKDCT3G4ZUEGIJYE-1200x640.jpeg)